Lennox-Gastaut Syndrome Treatment Decision Study
PI(s): Anne Berg and Marc Rosenman
Project Summary: In order to inform decision-making about treatment for Lennox-Gastaut Syndrome (LGS), researchers aim to determine the impact of Palliative Surgical Therapy (PST) and LGS-approved anti-seizure medications (LGS-ASM) on key clinical outcomes in children with LGS. Additionally, this study will delineate patterns of utilization for palliative surgical therapies for LGS and knowledge-attitude-practice barriers to their use. Eighteen PCORnet sites will contribute data to help researchers identify variation in practice due to site, trends over time, and variation in treatment practices by child's age, race, ethnicity, and insurance type. Through a mixed-methods, qualitative to quantitative approach at 8 sites, researchers will identify gaps in knowledge, attitudes, and practice among stakeholder communities that, if filled, could result in more optimal utilization of medical versus surgical therapies for LGS.
Study Design: Multi-CRN Data only Observational
PaTH Partners:
Sponsor: PCORI®
The Lennox-Gastaut Syndrome Treatment Decision Study study is a PCORnet® Study conducted using PCORnet®, the National PatientCentered Clinical Research Network, an initiative funded by the Patient-Centered Outcomes Research Institute (PCORI). More information about PCORnet® can be found here.
The Lennox-Gastaut Syndrome Treatment Decision Study was funded by PCORI through PCORI Award (RD-2020C2-20356).
The statements presented on this website are solely the responsibility of the author(s) and do not necessarily represent the views of other organizations participating in, collaborating with, or funding PCORnet or of PCORI.
Coordinating Center: Lurie Children’s Hospital